Introduction

Urothelial bladder cancer is the most common type of urinary tract cancer. In the United States, 76,960 cases and 16,390 deaths were estimated for 2016 (ACS 2016​).
Most bladder cancer is uroepithelial; less common subtypes are squamous cell and adenocarcinoma (NCI 2012). Early stages of bladder cancer are treated with surgery, radiation, or a combination of treatments including chemotherapy (NCI 2012). Tumor resection often leads to cure in early stage patients. Intravesical chemotherapy is also sometimes used. For patients with more advanced tumors, removal of the bladder is the most common treatment. Surgery may be followed by radiation or chemotherapy.
While targeted therapies are being investigated for use in advanced bladder cancer, progress has been slow. Promising targets for therapy include EGFR, FGFR3, mTOR, PIK3CA, RAS, and VEGF (Iyer et al. 2012; Saghedi and Garcia 2012; Sjodahl et al. 2011; Williams, Hurst, and Knowles 2012​).
Solit, D. 2016. Molecular Profiling of Bladder Cancer. My Cancer Genome

Guideline

No guideline available.

Case

No case available.

External Links

No data available.

Research Progress

No data available.

Curated Knowledge

The below lists the genes that has strong relation to bladder cancer.
Related references and evidence are provided.The badge shows that how many papers, studies, and other resources support the conclusion of the relationship.

No data available.

Statistics in Database

In this database, the most frequently mutated genes and most affected donors are below.

Most Frequently Mutated Genes

SymbolNameLocationLocus typeVariationsDonors affected
bladder cancerAll tumour type
SymbolNameLocationLocus typeVariationsbladder cancerAll tumour type

Statistics

Most Affected Donors

IDGenderAgePrimary siteVariationsAffected genes
IDGenderAgePrimary siteVariationsAffected genes